

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN

BRENTUXIMAB VEDOTIN

PRONUNCIATION

bren tuk' see mab ve doe' tin


THERAPEUTIC CLAIM

Treatment of Hodgkin's lymphoma, CD30-positive hematologic malignancies

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human CD30 (antigen)) (human-mouse monoclonal cAC10  $\gamma$ 1-chain), disulfide with human-mouse monoclonal cAC10  $\kappa$ -chain, dimer, complex with *N*-[[[4-[[*N*-[6-(2,5-dihydro-2,5-dioxo-1*H*-pyrrol-1-yl)-1-oxohexyl]-*L*-valyl-*N*<sup>δ</sup>-(aminocarbonyl)-*L*-ornithyl]amino]phenyl]methoxy]carbonyl]-*N*-methyl-*L*-valyl-*N*-[(1*S*,2*R*)-4-[(2*S*)-2-[(1*R*,2*R*)-3-[(1*R*,2*S*)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1*S*)-1-methylpropyl]-4-oxobutyl]-*N*-methyl-*L*-valinamide
2. Compound obtained by action of (4-[(2*S*)-5-(carbamoylamino)-2-[(2*S*)-2-[[6-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)hexanoyl]amino]-3-methylbutanoyl]amino} pentanoyl]amino}phenyl)methyl [(2*S*)-1-[(2*S*)-1-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[(1*S*,2*R*)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]methylamino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]methylcarbamate on immunoglobulin G1, anti-(human tumor necrosis factor receptor superfamily member 8 (lymphocyte activation antigen CD30 or KI-1 antigen); chimeric (mouse variable domain/human constant domain) monoclonal cAC10 des-Lys<sup>107</sup>-K)- $\gamma$ 1 heavy chain (220-218')-disulfide with chimeric (mouse variable domain/human constant domain) monoclonal cAC10  $\kappa$  light chain, dimer (226-226':229-229'')-bisdisulfide

STRUCTURAL FORMULA



MOLECULAR FORMULA

$C_{6476}H_{9930}N_{1690}O_{2030}S_{40} (C_{68}H_{105}N_{11}O_{15})_n$

TRADEMARK

None as yet

MANUFACTURER

Seattle Genetics, Inc.

CODE DESIGNATION

SGN-35, cAC10-vcMMAE

CAS REGISTRY NUMBER

914088-09-8